{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:57:56Z","timestamp":1789747076953,"version":"4.0.1"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["KYCX25_1052"],"award-info":[{"award-number":["KYCX25_1052"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20221522"],"award-info":[{"award-number":["BK20221522"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["2024-3-0230"],"award-info":[{"award-number":["2024-3-0230"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["2022-3-16-203"],"award-info":[{"award-number":["2022-3-16-203"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473781"],"award-info":[{"award-number":["82473781"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bmc.2026.118703","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:31:19Z","timestamp":1778758279000},"page":"118703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["PROTACs for central nervous system disorders: challenges and opportunities"],"prefix":"10.1016","volume":"139","author":[{"given":"Na","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jikuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baichen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoaoyun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haopeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118703_bb0005","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.13.04160","article-title":"Global, regional, and national burden of neurological disorders in 204 countries and territories worldwide","volume":"13","author":"Huang","year":"2023","journal-title":"J Glob Health"},{"issue":"3","key":"10.1016\/j.bmc.2026.118703_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030719","article-title":"Novel approaches for the treatment of Alzheimer\u2019s and Parkinson\u2019s disease","volume":"20","author":"Van Bulck","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.bmc.2026.118703_bb0015","first-page":"869","article-title":"New insight into targeting the DNA damage response in the treatment of glioblastoma","volume":"22","author":"Zhen","year":"2024","journal-title":"Chin J Nat Med"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41583-019-0240-3","article-title":"Amyloid-beta-independent regulators of tau pathology in Alzheimer disease","volume":"21","author":"van der Kant","year":"2020","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nan.12298","article-title":"Review: sporadic Parkinson\u2019s disease: development and distribution of -synuclein pathology","volume":"42","author":"Del Tredici","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"38","key":"10.1016\/j.bmc.2026.118703_bb0030","doi-asserted-by":"crossref","first-page":"11530","DOI":"10.1002\/anie.201706529","article-title":"Discovery of small molecules that induce the degradation of huntingtin","volume":"56","author":"Tomoshige","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"issue":"10","key":"10.1016\/j.bmc.2026.118703_bb0035","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s12276-020-00513-7","article-title":"The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies","volume":"52","author":"Jo","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.bmc.2026.118703_bb0040","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct Target Ther"},{"issue":"7748","key":"10.1016\/j.bmc.2026.118703_bb0045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/d41586-019-00879-3","article-title":"Protein-slaying drugs could be the next blockbuster therapies","volume":"567","author":"Scudellari","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0050","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/j.bmc.2026.118703_bb0055","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-019-0362-y","article-title":"Development of targeted protein degradation therapeutics","volume":"15","author":"Chamberlain","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2026.118703_bb0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-cancerbio-061824-105806","article-title":"Development of PROTAC degrader drugs for Cancer","volume":"9","author":"Vetma","year":"2025","journal-title":"Annu Rev Cancer Biol"},{"issue":"5","key":"10.1016\/j.bmc.2026.118703_bb0065","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/17568919.2025.2463310","article-title":"Advancements in PROTAC-based therapies for neurodegenerative diseases","volume":"17","author":"Kong","year":"2025","journal-title":"Future Med Chem"},{"issue":"10","key":"10.1016\/j.bmc.2026.118703_bb0070","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.4103\/1673-5374.308075","article-title":"Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system","volume":"16","author":"Ma","year":"2021","journal-title":"Neural Regen Res"},{"issue":"8","key":"10.1016\/j.bmc.2026.118703_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/biom13081164","article-title":"Central nervous system targeted protein degraders","volume":"13","author":"Thomas","year":"2023","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.bmc.2026.118703_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/cells8020098","article-title":"Targeting Hedgehog signalling through the ubiquitylation process: the multiple roles of the HECT-E3 ligase Itch","volume":"8","author":"Infante","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bmc.2026.118703_bb0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-biochem-060208-092442","article-title":"Molecular chaperone functions in protein folding and proteostasis","volume":"82","author":"Kim","year":"2013","journal-title":"Annu Rev Biochem"},{"issue":"9","key":"10.1016\/j.bmc.2026.118703_bb0090","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","article-title":"Targeted protein degradation: from chemical biology to drug discovery","volume":"24","author":"Cromm","year":"2017","journal-title":"Cell Chem. Biol."},{"issue":"2","key":"10.1016\/j.bmc.2026.118703_bb0095","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118703_bb0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fmolb.2020.00021","article-title":"Resolving the complexity of ubiquitin networks","volume":"7","author":"Kliza","year":"2020","journal-title":"Front Mol Biosci"},{"issue":"3","key":"10.1016\/j.bmc.2026.118703_bb0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"10.1016\/j.bmc.2026.118703_bb0110","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/bioinformatics\/bty1067","article-title":"UbiHub: a data hub for the explorers of ubiquitination pathways","volume":"35","author":"Liu","year":"2019","journal-title":"Bioinformatics"},{"issue":"26","key":"10.1016\/j.bmc.2026.118703_bb0115","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","article-title":"PROteolysis TArgeting chimeras (PROTACs) as emerging anticancer therapeutics","volume":"39","author":"Khan","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2026.118703_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2024.1370509","article-title":"Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?","volume":"17","author":"Kuemper","year":"2024","journal-title":"Front Mol Neurosci"},{"issue":"14","key":"10.1016\/j.bmc.2026.118703_bb0125","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem Soc Rev"},{"issue":"6","key":"10.1016\/j.bmc.2026.118703_bb0130","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central nervous system multiparameter optimization desirability: application in drug discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41597-021-01069-5","article-title":"A curated diverse molecular database of blood-brain barrier permeability with chemical descriptors","volume":"8","author":"Meng","year":"2021","journal-title":"Sci Data"},{"issue":"3","key":"10.1016\/j.bmc.2026.118703_bb0140","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1042\/BJ20141450","article-title":"Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation","volume":"467","author":"Bulatov","year":"2015","journal-title":"Biochem J"},{"issue":"5971","key":"10.1016\/j.bmc.2026.118703_bb0145","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bmc.2026.118703_bb0150","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.45457","article-title":"Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models","volume":"8","author":"Silva","year":"2019","journal-title":"Elife"},{"issue":"37","key":"10.1016\/j.bmc.2026.118703_bb0155","doi-asserted-by":"crossref","first-page":"16930","DOI":"10.1021\/jacs.2c05499","article-title":"Discovery of XL01126: a potent, fast, cooperative, selective, orally bioavailable, and blood-brain barrier penetrant PROTAC degrader of leucine-rich repeat kinase 2","volume":"144","author":"Liu","year":"2022","journal-title":"J Am Chem Soc"},{"issue":"19","key":"10.1016\/j.bmc.2026.118703_bb0160","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1039\/D2CS00387B","article-title":"Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders","volume":"51","author":"Diehl","year":"2022","journal-title":"Chem Soc Rev"},{"issue":"24","key":"10.1016\/j.bmc.2026.118703_bb0165","doi-asserted-by":"crossref","first-page":"18082","DOI":"10.1021\/acs.jmedchem.1c01496","article-title":"Amide-to-Ester substitution as a strategy for optimizing PROTAC permeability and cellular activity","volume":"64","author":"Klein","year":"2021","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bmc.2026.118703_bb0170","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.bmc.2026.118703_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073948","article-title":"The MDM2-p53 axis represents a therapeutic vulnerability unique to glioma stem cells","volume":"25","author":"Nakagawa-Saito","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.bmc.2026.118703_bb0180","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrd4236","article-title":"Drugging the p53 pathway: understanding the route to clinical efficacy","volume":"13","author":"Khoo","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.bmc.2026.118703_bb0185","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0190","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1158\/0008-5472.CAN-18-2918","article-title":"MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53","volume":"79","author":"Hines","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118703_bb0195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ddtec.2018.12.002","article-title":"SNIPERs-hijacking IAP activity to induce protein degradation","volume":"31","author":"Naito","year":"2019","journal-title":"Drug Discov Today Technol"},{"issue":"11","key":"10.1016\/j.bmc.2026.118703_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21113921","article-title":"The role of tissue-specific ubiquitin ligases, RNF183, RNF186, RNF182 and RNF152, in disease and biological function","volume":"21","author":"Okamoto","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.bmc.2026.118703_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2025.151483","article-title":"The dual nature of KLHL proteins: from cellular regulators to disease drivers","volume":"104","author":"Di Giulio","year":"2025","journal-title":"Eur J Cell Biol"},{"issue":"15","key":"10.1016\/j.bmc.2026.118703_bb0210","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1039\/D2CS00116K","article-title":"Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders","volume":"51","author":"Yamamoto","year":"2022","journal-title":"Chem Soc Rev"},{"issue":"2","key":"10.1016\/j.bmc.2026.118703_bb0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12031-025-02337-4","article-title":"Unraveling the complexity of Alzheimer\u2019s disease: insights into Etiology and advancements in treatment strategies","volume":"75","author":"Khan","year":"2025","journal-title":"J Mol Neurosci"},{"issue":"2","key":"10.1016\/j.bmc.2026.118703_bb0220","article-title":"Alzheimer\u2019s disease drug development pipeline: 2025","volume":"11","author":"Cummings","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0225","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid beta-based therapy for Alzheimer\u2019s disease: challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"suppl 5","key":"10.1016\/j.bmc.2026.118703_bb0230","article-title":"Drug development","volume":"21","author":"Ackley","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"10","key":"10.1016\/j.bmc.2026.118703_bb0235","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00018-016-2168-3","article-title":"Microtubule plus-end tracking proteins in neuronal development","volume":"73","author":"van de Willige","year":"2016","journal-title":"Cell Mol Life Sci"},{"issue":"21","key":"10.1016\/j.bmc.2026.118703_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112841","article-title":"Phosphorylated tau in Alzheimer\u2019s disease and other tauopathies","volume":"23","author":"Rawat","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0245","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40035-023-00395-5","article-title":"Death-associated protein kinase 1 as a therapeutic target for Alzheimer\u2019s disease","volume":"13","author":"Zhang","year":"2024","journal-title":"Transl Neurodegener"},{"issue":"4","key":"10.1016\/j.bmc.2026.118703_bb0250","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1007\/s12035-018-1242-2","article-title":"DAPK1: a novel pathology and treatment target for Alzheimer\u2019s disease","volume":"56","author":"Xu","year":"2018","journal-title":"Mol Neurobiol"},{"issue":"2","key":"10.1016\/j.bmc.2026.118703_bb0255","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1021\/acschemneuro.8b00457","article-title":"Pathological changes of tau related to Alzheimer\u2019s disease","volume":"10","author":"Chu","year":"2019","journal-title":"ACS Chem Neurosci"},{"issue":"8","key":"10.1016\/j.bmc.2026.118703_bb0260","article-title":"Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer\u2019s disease and tauopathies","volume":"1867","author":"Jangampalli","year":"2021","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0265","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"10.1016\/j.bmc.2026.118703_bb0270","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.chembiol.2016.02.016","article-title":"Specific knockdown of endogenous tau protein by peptide-directed ubiquitin-proteasome degradation","volume":"23","author":"Chu","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bmc.2026.118703_bb0275","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejmech.2018.01.063","article-title":"Discovery of a Keap1-dependent peptide PROTAC to knockdown tau by ubiquitination-proteasome degradation pathway","volume":"146","author":"Lu","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2026.118703_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70133","article-title":"The peptide PROTAC modality: a new strategy for drug discovery","volume":"6","author":"Zhu","year":"2025","journal-title":"MedComm"},{"issue":"2","key":"10.1016\/j.bmc.2026.118703_bb0285","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2174\/0929867330666230130121822","article-title":"Peptide-based PROTACs: current challenges and future perspectives","volume":"31","author":"Wang","year":"2024","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2026.118703_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.801179","article-title":"Discovery and optimization of tau targeted protein degraders enabled by patient induced pluripotent stem cells-derived neuronal models of tauopathy","volume":"16","author":"Silva","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.bmc.2026.118703_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1351792","article-title":"Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer\u2019s disease model mice","volume":"15","author":"Yao","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2026.118703_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103970","article-title":"Human tau accumulation promotes glycogen synthase kinase-3beta acetylation and thus upregulates the kinase: a vicious cycle in Alzheimer neurodegeneration","volume":"78","author":"Zhou","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bmc.2026.118703_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112949","article-title":"PROTACs suppression of GSK-3beta, a crucial kinase in neurodegenerative diseases","volume":"210","author":"Jiang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118703_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113889","article-title":"Discovery of PT-65 as a highly potent and selective proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer\u2019s disease","volume":"226","author":"Qu","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"11","key":"10.1016\/j.bmc.2026.118703_bb0315","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1021\/acschemneuro.3c00096","article-title":"PROTAC-induced glycogen synthase kinase 3beta degradation as a potential therapeutic strategy for Alzheimer\u2019s disease","volume":"14","author":"Guardigni","year":"2023","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmc.2026.118703_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109044","article-title":"Design, synthesis, and biological evaluation of death-associated protein kinase 1 PROTACs","volume":"165","author":"Wu","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118703_bb0325","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2016.11.009","article-title":"Changes in neural circuitry associated with depression at pre-clinical, pre-motor and early motor phases of Parkinson\u2019s disease","volume":"35","author":"Borgonovo","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"issue":"13","key":"10.1016\/j.bmc.2026.118703_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/cells11132097","article-title":"Hallmarks and molecular tools for the study of mitophagy in Parkinson\u2019s disease","volume":"11","author":"Goiran","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bmc.2026.118703_bb0335","doi-asserted-by":"crossref","DOI":"10.1177\/1877718X251354935","article-title":"Gaps in the Parkinson\u2019s disease therapeutic clinical pipeline: a focus on approaches targeting disease pathobiology","author":"Koros","year":"2025","journal-title":"J Parkinsons Dis"},{"issue":"8","key":"10.1016\/j.bmc.2026.118703_bb0340","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.bmc.2026.118703_bb0345","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/jnc.14965","article-title":"Synucleinopathies: where we are and where we need to go","volume":"153","author":"Br\u00e1s","year":"2020","journal-title":"J Neurochem"},{"issue":"6","key":"10.1016\/j.bmc.2026.118703_bb0350","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.chembiol.2020.03.010","article-title":"Specific knockdown of \u03b1-synuclein by peptide-directed proteasome degradation rescued its associated neurotoxicity","volume":"27","author":"Qu","year":"2020","journal-title":"Cell Chem Biol"},{"issue":"8","key":"10.1016\/j.bmc.2026.118703_bb0355","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nchembio.598","article-title":"Small-molecule displacement of a cryptic degron causes conditional protein degradation","volume":"7","author":"Bonger","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"6","key":"10.1016\/j.bmc.2026.118703_bb0360","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/acsmedchemlett.0c00192","article-title":"PROTAC compounds targeting alpha-synuclein protein for treating neurogenerative disorders: Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med Chem Lett"},{"issue":"11","key":"10.1016\/j.bmc.2026.118703_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28114458","article-title":"Design, synthesis and biological evaluation of alpha-synuclein proteolysis-targeting chimeras","volume":"28","author":"Wen","year":"2023","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.bmc.2026.118703_bb0370","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1021\/acs.jmedchem.3c00274","article-title":"Discovery of small-molecule degraders for alpha-synuclein aggregates","volume":"66","author":"Tong","year":"2023","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.bmc.2026.118703_bb0375","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.parkreldis.2010.11.008","article-title":"Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson\u2019s disease","volume":"17","author":"Bardien","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0380","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1186\/s12967-025-06354-0","article-title":"Recent advances in targeting LRRK2 for Parkinson\u2019s disease treatment","volume":"23","author":"Karami","year":"2025","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.bmc.2026.118703_bb0385","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","article-title":"LRRK2 in Parkinson disease: challenges of clinical trials","volume":"16","author":"Tolosa","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"10.1016\/j.bmc.2026.118703_bb0390","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cmdc.202000872","article-title":"The tale of proteolysis targeting chimeras (PROTACs) for leucine-rich repeat kinase 2 (LRRK2)","volume":"16","author":"Konstantinidou","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2026.118703_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129861","article-title":"Stereochemical inversion at a 1,4-cyclohexyl PROTAC linker fine-tunes conformation and binding affinity","volume":"110","author":"Pierri","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118703_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129449","article-title":"Development of a highly potent and selective degrader of LRRK2","volume":"94","author":"Hatcher","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118703_bb0405","unstructured":"Arvinas. Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC\u00ae Protein Degrader for Neurodegenerative Disease. Accessed 5 May 2026. https:\/\/ir.arvinas.com\/news-releases\/news-release-details\/arvinas-announces-first-human-dosing-arv-102-investigational?mc_cid=5729cac5723."},{"key":"10.1016\/j.bmc.2026.118703_bb0410","unstructured":"Arvinas. Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation. Accessed 5 May 2026. https:\/\/ir.arvinas.com\/news-releases\/news-release-details\/arvinas-presents-first-human-data-investigational-oral-protac."},{"key":"10.1016\/j.bmc.2026.118703_bb0415","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","article-title":"Genetics and neuropathology of Huntington\u2019s disease","volume":"98","author":"Reiner","year":"2011","journal-title":"Int Rev Neurobiol"},{"issue":"2","key":"10.1016\/j.bmc.2026.118703_bb0420","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/18796397251337000","article-title":"Huntington\u2019s disease clinical trials update: march 2025","volume":"14","author":"Farag","year":"2025","journal-title":"J Huntingtons Dis"},{"issue":"20","key":"10.1016\/j.bmc.2026.118703_bb0425","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","article-title":"A worldwide study of the Huntington\u2019s disease mutation. The sensitivity and specificity of measuring CAG repeats","volume":"330","author":"Kremer","year":"1994","journal-title":"N Engl J Med"},{"issue":"5334","key":"10.1016\/j.bmc.2026.118703_bb0430","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bmc.2026.118703_bb0435","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.bmc.2026.118703_bb0440","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2478\/jtim-2023-0142","article-title":"Latest advances on new promising molecular-based therapeutic approaches for Huntington\u2019s disease","volume":"12","author":"Cheng","year":"2024","journal-title":"J Transl Int Med"},{"issue":"4","key":"10.1016\/j.bmc.2026.118703_bb0445","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bmcl.2018.01.012","article-title":"Degradation of huntingtin mediated by a hybrid molecule composed of IAP antagonist linked to phenyldiazenyl benzothiazole derivative","volume":"28","author":"Tomoshige","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/j.bmc.2026.118703_bb0450","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","article-title":"TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"351","author":"Arai","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"5796","key":"10.1016\/j.bmc.2026.118703_bb0455","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.1134108","article-title":"Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"314","author":"Neumann","year":"2006","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bmc.2026.118703_bb0460","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs","volume":"39","author":"Jaiswal","year":"2019","journal-title":"Med Res Rev"},{"issue":"4","key":"10.1016\/j.bmc.2026.118703_bb0465","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/21678421.2012.734520","article-title":"Identification of RNA bound to the TDP-43 ribonucleoprotein complex in the adult mouse brain","volume":"14","author":"Narayanan","year":"2013","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.bmc.2026.118703_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104534","article-title":"Non-genetically modified models exhibit TARDBP mRNA increase due to perturbed TDP-43 autoregulation","volume":"130","author":"Sugai","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"6","key":"10.1016\/j.bmc.2026.118703_bb0475","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/14728222.2022.2083958","article-title":"TAR DNA-binding protein of 43 kDa (TDP-43) and amyotrophic lateral sclerosis (ALS): a promising therapeutic target","volume":"26","author":"Ojaimi","year":"2022","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0480","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12929-023-00921-7","article-title":"Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera","volume":"30","author":"Tseng","year":"2023","journal-title":"J Biomed Sci"},{"issue":"8","key":"10.1016\/j.bmc.2026.118703_bb0485","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of Tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology."},{"issue":"23","key":"10.1016\/j.bmc.2026.118703_bb0490","doi-asserted-by":"crossref","first-page":"15642","DOI":"10.1021\/acs.jmedchem.2c00771","article-title":"Identification and characterization of a novel indoleamine 2,3-dioxygenase 1 protein degrader for glioblastoma","volume":"65","author":"Bollu","year":"2022","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2026.118703_bb0495","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1021\/acs.jmedchem.5c00026","article-title":"Rational design and optimization of a potent IDO1 proteolysis targeting chimera (PROTAC)","volume":"68","author":"Monsen","year":"2025","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0500","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41420-025-02392-1","article-title":"MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell","volume":"11","author":"Yuan","year":"2025","journal-title":"Cell Death Discovery"},{"issue":"12","key":"10.1016\/j.bmc.2026.118703_bb0505","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.3390\/molecules29122812","article-title":"Role of tau protein in neurodegenerative diseases and development of its targeted drugs: a literature review","volume":"29","author":"Yang","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2026.118703_bb0510","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bbrc.2021.03.091","article-title":"Tau induces formation of alpha-synuclein filaments with distinct molecular conformations","volume":"554","author":"Hojjatian","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.bmc.2026.118703_bb0515","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1021\/acs.jmedchem.3c01719","article-title":"Discovery of effective dual PROTAC degraders for neurodegenerative disease-associated aggregates","volume":"67","author":"Zhu","year":"2024","journal-title":"J Med Chem"},{"issue":"49","key":"10.1016\/j.bmc.2026.118703_bb0520","doi-asserted-by":"crossref","first-page":"22622","DOI":"10.1021\/jacs.2c09255","article-title":"Bridged proteolysis targeting chimera (PROTAC) enables degradation of undruggable targets","volume":"144","author":"Xiong","year":"2022","journal-title":"J Am Chem Soc"},{"issue":"8","key":"10.1016\/j.bmc.2026.118703_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110449","article-title":"Targeted degradation of alpha-synuclein by arginine-based PROTACs","volume":"301","author":"Shen","year":"2025","journal-title":"J Biol Chem"},{"issue":"36","key":"10.1016\/j.bmc.2026.118703_bb0530","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202508538","article-title":"Chemical proteomics identifies RBBP7 as a new E3 ligase supporting targeted protein degradation","volume":"64","author":"Liu","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0535","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1038\/s41467-020-17997-6","article-title":"Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry","volume":"11","author":"Guo","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.bmc.2026.118703_bb0540","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2533\/chimia.2022.341","article-title":"Linkers as game-changers in PROTAC technology: emphasizing general trends in PROTAC pharmacokinetics for their rational design","volume":"76","author":"Cecchini","year":"2022","journal-title":"Chimia"},{"issue":"16","key":"10.1016\/j.bmc.2026.118703_bb0545","doi-asserted-by":"crossref","first-page":"13328","DOI":"10.1021\/jacs.4c18354","article-title":"Rational design of PROTAC linkers featuring ferrocene as a molecular hinge to enable dynamic conformational changes","volume":"147","author":"Salerno","year":"2025","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0550","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1038\/s41467-025-60107-7","article-title":"Linker-free PROTACs efficiently induce the degradation of oncoproteins","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.bmc.2026.118703_bb0555","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.31255","article-title":"Restraining the power of proteolysis targeting chimeras in the cage: a necessary and important refinement for therapeutic safety","volume":"239","author":"Zhang","year":"2024","journal-title":"J Cell Physiol"},{"issue":"12","key":"10.1016\/j.bmc.2026.118703_bb0560","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.bmc.2026.118703_bb0565","doi-asserted-by":"crossref","first-page":"14155","DOI":"10.1021\/jacs.3c05159","article-title":"Bioorthogonal PROTAC prodrugs enabled by on-target activation","volume":"145","author":"Chang","year":"2023","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2026.118703_bb0570","doi-asserted-by":"crossref","unstructured":"Xu Q.; Hu X.; Ullah I., et al. Biomimetic hybrid PROTAC nanovesicles block multiple DNA repair pathways to overcome temozolomide resistance against orthotopic glioblastoma. Adv. Mater. (Weinheim, Ger.). 2025, Vol. 37(29), e2504253. doi:https:\/\/doi.org\/10.1002\/adma.202504253, Adv Mater.","DOI":"10.1002\/adma.202504253"},{"issue":"9","key":"10.1016\/j.bmc.2026.118703_bb0575","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1016\/j.apsb.2025.06.028","article-title":"Activatable PROTAC nanoassembly for photodynamic PTP1B proteolysis enhances glioblastoma immunotherapy","volume":"15","author":"Jang","year":"2025","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"10.1016\/j.bmc.2026.118703_bb0580","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/antib12030043","article-title":"Proteolysis-targeting chimera (PROTAC) delivery into the brain across the blood-brain barrier","volume":"12","author":"Tashima","year":"2023","journal-title":"Antibodies"},{"issue":"7","key":"10.1016\/j.bmc.2026.118703_bb0585","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/14712598.2023.2227378","article-title":"Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies","volume":"23","author":"Singh Gautam","year":"2023","journal-title":"Expert Opin Biol Ther"},{"issue":"18","key":"10.1016\/j.bmc.2026.118703_bb0590","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1021\/acschemneuro.5c00484","article-title":"Antibody therapies for Alzheimer\u2019s disease: a new strategy for targeted therapy and blood-brain barrier delivery","volume":"16","author":"Feng","year":"2025","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"10.1016\/j.bmc.2026.118703_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/antib8020027","article-title":"Single-domain antibodies as therapeutic and imaging agents for the treatment of CNS diseases","volume":"8","author":"Belanger","year":"2019","journal-title":"Antibodies"},{"issue":"6428","key":"10.1016\/j.bmc.2026.118703_bb0600","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"issue":"6518","key":"10.1016\/j.bmc.2026.118703_bb0605","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/374168a0","article-title":"A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks","volume":"374","author":"Greenberg","year":"1995","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0610","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1038\/s41598-023-31568-x","article-title":"Rabbit derived VL single-domains as promising scaffolds to generate antibody-drug conjugates","volume":"13","author":"Andre","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0615","doi-asserted-by":"crossref","first-page":"17747","DOI":"10.1038\/s41598-024-68680-5","article-title":"A single-domain antibody library based on a stability-engineered human VH3 scaffold","volume":"14","author":"Lee","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2026.118703_bb0620","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1426656","article-title":"Single-domain antibodies and aptamers drive new opportunities for neurodegenerative disease research","volume":"15","author":"Shoemaker","year":"2024","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.bmc.2026.118703_bb0625","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071452","article-title":"Brain delivery of IGF1R5, a single-domain antibody targeting insulin-like growth factor-1 receptor","volume":"14","author":"Yogi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.bmc.2026.118703_bb0630","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071335","article-title":"A single domain shark antibody targeting the transferrin receptor 1 delivers a TrkB agonist antibody to the brain and provides full neuroprotection in a mouse model of Parkinson\u2019s disease","volume":"14","author":"Clarke","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0635","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13024-024-00730-y","article-title":"Single-domain antibody-based protein degrader for synucleinopathies","volume":"19","author":"Jiang","year":"2024","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.bmc.2026.118703_bb0640","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.biopha.2018.09.097","article-title":"Cell penetrating peptides: a concise review with emphasis on biomedical applications","volume":"108","author":"Derakhshankhah","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"44","key":"10.1016\/j.bmc.2026.118703_bb0645","doi-asserted-by":"crossref","first-page":"14727","DOI":"10.1523\/JNEUROSCI.1304-15.2015","article-title":"Cell-permeable peptide targeting the Nrf2-Keap1 interaction: a potential novel therapy for global cerebral ischemia","volume":"35","author":"Tu","year":"2015","journal-title":"J Neurosci"},{"issue":"9","key":"10.1016\/j.bmc.2026.118703_bb0650","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.3390\/pharmaceutics14091874","article-title":"Peptide shuttles for blood-brain barrier drug delivery","volume":"14","author":"Sanchez-Navarro","year":"2022","journal-title":"Pharmaceutics"},{"issue":"47","key":"10.1016\/j.bmc.2026.118703_bb0655","doi-asserted-by":"crossref","first-page":"25753","DOI":"10.1021\/jacs.3c09240","article-title":"Peptide-mimicking poly(2-oxazoline)s possessing potent antifungal activity and BBB penetrating property to treat invasive infections and meningitis","volume":"145","author":"Jiang","year":"2023","journal-title":"J Am Chem Soc"},{"issue":"3","key":"10.1016\/j.bmc.2026.118703_bb0660","doi-asserted-by":"crossref","first-page":"eadr8841","DOI":"10.1126\/sciadv.adr8841","article-title":"Peptide-drug conjugates repolarize glioblastoma-associated macrophages to resensitize chemo-immunotherapy of glioblastoma","volume":"11","author":"Li","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.bmc.2026.118703_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116734","article-title":"Discovery of novel penetrating peptides able to target human leukemia and lymphoma for enhanced PROTAC delivery","volume":"277","author":"Zhang","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"31","key":"10.1016\/j.bmc.2026.118703_bb0670","doi-asserted-by":"crossref","first-page":"27862","DOI":"10.1021\/jacs.5c07041","article-title":"A covalent self-reporting peptide degrader enables real-time monitoring of targeted protein degradation in vivo","volume":"147","author":"Zhang","year":"2025","journal-title":"J Am Chem Soc"},{"issue":"11","key":"10.1016\/j.bmc.2026.118703_bb0675","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/s41587-024-02487-7","article-title":"Intravenous administration of blood-brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system","volume":"43","author":"Wang","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"17","key":"10.1016\/j.bmc.2026.118703_bb0680","doi-asserted-by":"crossref","first-page":"11454","DOI":"10.1021\/acs.jmedchem.2c00844","article-title":"Progress and challenges in targeted protein degradation for neurodegenerative disease therapy","volume":"65","author":"Fang","year":"2022","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.bmc.2026.118703_bb0685","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/anie.202004746","article-title":"PROTACs and other chemical protein degradation Technologies for the Treatment of neurodegenerative disorders","volume":"60","author":"Tomoshige","year":"2021","journal-title":"AngewChem Int Ed"},{"issue":"15","key":"10.1016\/j.bmc.2026.118703_bb0690","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","article-title":"Molecular glues for targeted protein degradation: from serendipity to rational discovery","volume":"64","author":"Dong","year":"2021","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0695","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09358-9","article-title":"Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction","volume":"10","author":"Simonetta","year":"2019","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.bmc.2026.118703_bb0700","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41589-020-0594-x","article-title":"Rational discovery of molecular glue degraders via scalable chemical profiling","volume":"16","author":"Mayor-Ruiz","year":"2020","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0705","article-title":"Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression","volume":"6","author":"Aquilanti","year":"2024","journal-title":"Neurooncol Adv"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0710","doi-asserted-by":"crossref","first-page":"7707","DOI":"10.1038\/s41467-024-51889-3","article-title":"Activation of parkin by a molecular glue","volume":"15","author":"Sauve","year":"2024","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.bmc.2026.118703_bb0715","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70537","article-title":"Randomized phase 2a trial assessing a novel septin molecular glue in Alzheimer\u2019s disease","volume":"21","author":"Nuytten","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2025.100295","article-title":"Hydrophobic tagging: a promising paradigm for targeted protein degradation","volume":"5","author":"Xin","year":"2026","journal-title":"Cell Insight"},{"issue":"64","key":"10.1016\/j.bmc.2026.118703_bb0725","doi-asserted-by":"crossref","first-page":"40362","DOI":"10.1039\/C7RA05347A","article-title":"Hydrophobic tagging-mediated degradation of Alzheimer\u2019s disease related tau","volume":"7","author":"Gao","year":"2017","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2026.118703_bb0730","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.bioorg.2018.11.042","article-title":"TDP-43 specific reduction induced by Di-hydrophobic tags conjugated peptides","volume":"84","author":"Gao","year":"2019","journal-title":"Bioorg Chem"},{"issue":"3","key":"10.1016\/j.bmc.2026.118703_bb0735","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1021\/acsmedchemlett.1c00500","article-title":"Conversion of a PROTAC mutant huntingtin degrader into small-molecule hydrophobic tags focusing on drug-like properties","volume":"13","author":"Hirai","year":"2022","journal-title":"ACS Med Chem Lett"},{"issue":"8","key":"10.1016\/j.bmc.2026.118703_bb0740","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.chembiol.2019.07.015","article-title":"RIBOTACs: small molecules target RNA for degradation","volume":"26","author":"Dey","year":"2019","journal-title":"Cell Chem. Biol."},{"issue":"4","key":"10.1016\/j.bmc.2026.118703_bb0745","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1534","article-title":"RNA regulation of the antiviral protein 2\u2032-5\u2032-oligoadenylate synthetase","volume":"10","author":"Schwartz","year":"2019","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"17","key":"10.1016\/j.bmc.2026.118703_bb0750","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1021\/acs.jmedchem.9b01927","article-title":"How we think about targeting RNA with small molecules","volume":"63","author":"Costales","year":"2020","journal-title":"J Med Chem"},{"issue":"617","key":"10.1016\/j.bmc.2026.118703_bb0755","doi-asserted-by":"crossref","first-page":"eabd5991","DOI":"10.1126\/scitranslmed.abd5991","article-title":"Ribonuclease recruitment using a small molecule reduced c9ALS\/FTD r(G(4)C(2)) repeat expansion in vitro and in vivo ALS models","volume":"13","author":"Bush","year":"2021","journal-title":"Sci Transl Med"},{"issue":"7820","key":"10.1016\/j.bmc.2026.118703_bb0760","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bmc.2026.118703_bb0765","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.chembiol.2021.02.024","article-title":"Degradation from the outside in: targeting extracellular and membrane proteins for degradation through the endolysosomal pathway","volume":"28","author":"Ahn","year":"2021","journal-title":"Cell Chem Biol"},{"issue":"9","key":"10.1016\/j.bmc.2026.118703_bb0770","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat Chem Biol"},{"issue":"7","key":"10.1016\/j.bmc.2026.118703_bb0775","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.chempr.2023.06.003","article-title":"Biomarker-activated multifunctional lysosome-targeting chimeras mediated selective degradation of extracellular amyloid fibrils","volume":"9","author":"Liu","year":"2023","journal-title":"Chem"},{"key":"10.1016\/j.bmc.2026.118703_bb0780","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.769184","article-title":"Molecular strategies to target protein aggregation in Huntington\u2019s disease","volume":"8","author":"Jarosinska","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"3","key":"10.1016\/j.bmc.2026.118703_bb0785","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1039\/D1CB00011J","article-title":"Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation","volume":"2","author":"Bond","year":"2021","journal-title":"RSC Chem Biol"},{"issue":"5","key":"10.1016\/j.bmc.2026.118703_bb0790","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: cargo-specific degraders using selective autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol Cell"},{"issue":"10","key":"10.1016\/j.bmc.2026.118703_bb0795","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/j.apsb.2021.02.016","article-title":"Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson\u2019s disease","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"9","key":"10.1016\/j.bmc.2026.118703_bb0800","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1080\/15548627.2022.2091338","article-title":"Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting chimera)","volume":"18","author":"Ji","year":"2022","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.bmc.2026.118703_bb0805","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13024-023-00630-7","article-title":"Targeted degradation of \u237a-synuclein aggregates in Parkinson\u2019s disease using the AUTOTAC technology","volume":"18","author":"Lee","year":"2023","journal-title":"Mol Neurodegener"},{"issue":"7","key":"10.1016\/j.bmc.2026.118703_bb0810","first-page":"637","article-title":"Chaperone-mediated autophagy in cancer: advances from bench to bedside","volume":"35","author":"Hou","year":"2020","journal-title":"Histol Histopathol"},{"issue":"3","key":"10.1016\/j.bmc.2026.118703_bb0815","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nn.3637","article-title":"Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation","volume":"17","author":"Fan","year":"2014","journal-title":"Nat Neurosci"},{"issue":"10","key":"10.1016\/j.bmc.2026.118703_bb0820","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s13238-021-00858-3","article-title":"Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model","volume":"12","author":"Xu","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.bmc.2026.118703_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115911","article-title":"Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques","volume":"262","author":"Chen","year":"2023","journal-title":"Eur J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:09:39Z","timestamp":1783109379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":165,"alternative-id":["S0968089626001598"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118703","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PROTACs for central nervous system disorders: challenges and opportunities","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118703"}}